ArticleClinical and experimental nephrology2026
Rituximab vs. cyclophosphamide in treatment-naive IMN: efficacy and renal protection in early renal impairment.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCyclophosphamide (CTX) combined with glucocorticoids and rituximab (RTX) are widely used for idiopathic membranous nephropathy (IMN), but clinical data comparing them in newly diagnosed patients with impaired renal function (eGFR < 60 mL/min/1.73 m
methodsA retrospective study was conducted at the First Affiliated Hospital of Wannan Medical University from November 2019 to July 2024, including 113 newly diagnosed IMN patients (55 in the CTX group, 58 in the RTX group) diagnosed by renal biopsy or positive PLA2R antibodies. All patients were treatment-naive and followed for ≥ 6 months.
resultsAt 6 months, composite remission rates were 69.09% in the CTX group and 62.07% in the RTX group (P > 0.05). At 12 months, the RTX group showed a numerically higher composite remission rate (83.87% vs. 70.83% in CTX group) without statistical significance (P = 0.186). By 18 months, both groups reached 73.68% composite remission (P = 1.000). In the subgroup with eGFR < 60 mL/min/1.73 m
conclusionRTX shows comparable efficacy and better safety relative to CTX in this cohort, and may be a preferred option for newly diagnosed untreated IMN, especially in those with early renal impairment. RTX demonstrated comparable efficacy to CTX in newly diagnosed IMN but with superior safety. Notably, RTX showed greater short-term (6-month) renal function improvement in patients with early renal impairment, though long-term effects need further verification in larger-sample prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.